Korean J Urol.
2005 Jul;46(7):677-682.
Effect of Intravesical High Dose Epirubicin versus Bacillus Calmette-Guerin Instillation on the Recurrence and Progression of Superficial Bladder Cancer: A Prospective, Multicenter Study
- Affiliations
-
- 1Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Korea. sjhong346@yumc.yonsei.ac.kr
- 2Department of Urology, College of Medicine, Sungkyunkwan, Korea.
- 3Department of Urology, College of Medicine, Ulsan University, Korea.
- 4Department of Urology, College of Medicine, Inje University, Seoul, Korea.
Abstract
-
PURPOSE: To investigate the effects of intravesical high dose epirubicin instillation, the effect of epirubicin was compared with that of Bacillus Calmette-Guerin (BCG) instillation on the recurrence and progression of superficial bladder cancer.
MATERIALS AND METHODS
Between September 1999 and February 2002, a total of 174 patients, who received an 8-week course of high dose epirubicin (80mg/50ml) or a 6-week course of BCG, following a complete transurethral resection for superficial bladder cancer, were followed up. The recurrence-free survival (RFS) and progression-free survival (PFS) rates were analyzed in each groups.
RESULTS
There were no significant differences in the overall RFS and PFS between the two groups. In the high risk group, the RFS of the BCG group was significantly higher than that of the epirubicin group (p=0.014), whereas there was no significant difference in the PFS. In the intermediate risk group, there were no significant differences in the RFS and PFS. However, when those patients with a previous history of bladder cancer were excluded, the RFS was significantly higher in the epirubicin group (p= 0.0036). The incidence of local complications was higher in the high dose epirubicin group, but most of these were mild and self-limiting.
CONCLUSIONS
Intravesical high dose epirubicin instillation in the high risk superficial bladder cancer group had no benefit over that of BCG instillation in terms of RFS and complications. However, high dose epirubicin could be a good alternative for patients in the intermediate risk group and, so it would seem, for those with a first occurrence.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Prophylactic Effect of Intravesical Epirubicin and Bacillus Calmette- Guerin Therapy in Stage T1 Bladder Cancer
- Initial Experiences of Intravesical Gemcitabine Instillation Followed by Bacillus Calmette-Guerin(BCG) Therapy for Treating Intermediate or High Risk Patients with Superficial Bladder Cancer
- Univariate and Multivariate Analysis of the Factors in Recurrence and Progression of Superficial Bladder Cancer
- Evaluation of T-subsets and NK cell activity in patients with superficial bladder cancer after intravesical treatment with bacillus calmette-guerin
- Tuberculous Prostatic Abscess Following Intravesical Bacillus Calmette-Guerin Instillation
